

Diabetic Moms' Breastfed Kids May Stay Lean

BY KERRI WACHTER

FROM DIABETES CARE

Breastfeeding appears to have a protective effect against later obesity for children born to mothers with diabetes during pregnancy, based on an analysis of data from a retrospective cohort study.

The findings could help to prevent childhood obesity in children born to mothers with diabetes during pregnancy. Research has shown that these children have a greater prevalence of obesity in childhood, Tessa L. Crume, Ph.D., of the Colorado School of Public Health at the University of Colorado in Denver and her coinvestigators noted (*Diabetes Care* 2011;34:641-5).

Both children exposed to diabetes in utero and those unexposed but who had adequate breastfeeding had significantly lower body mass index (BMI), waist circumference, subcutaneous adipose tissue (SAT), and visceral adipose tissue (VAT) at ages 6-13 years than did those who breastfed less.

"Our study provides novel evidence that the effect of exposure to diabetes in utero on childhood adiposity parameters is substantially attenuated by breastfeeding, such that the obesity outcomes in exposed youth who were adequately breastfed were similar to those of unexposed youth. Our data suggest that breastfeeding promotion may be an effective strategy for reducing the increased risk of childhood obesity in the offspring of mothers with diabetes during pregnancy," wrote Dr. Crume and her colleagues.

The researchers used data from a retrospective cohort study entitled Exploring Perinatal Outcomes Among Children (EPOCH). Participants were aged 6-13 years. In addition, they were multi-ethnic offspring of singleton pregnancies born at a single hospital in Denver between 1992 and 2002. The mothers were members of the Kaiser Permanente of Colorado Health Plan and were still members and living in Colorado over the study period (2006-2009).

The study included 89 youths who were exposed to diabetes in utero. The researchers also identified a random sample of 397 children who were not exposed to diabetes in utero. Children and their biologic mothers were invited for a research visit during January 2006 to October 2009.

Physician-diagnosed maternal diabetes status was ascertained from the Kaiser Permanente Colorado perinatal database – an electronic database linking neonatal and perinatal medical records. All pregnant women were offered screening at 24-28 weeks. Exposure to diabetes in utero was defined as the presence of preexistent diabetes or gestational diabetes diagnosed during the index pregnancy. Birth weight, gestational age, and maternal prepregnancy weight also were obtained from the database.

Mothers were asked about breastfeeding and formula feeding, timing, and the introduction of other solid foods and beverages. Mixed feeding was common-

ly reported, so a measure of breast milk-months was developed that incorporated duration and exclusivity. Based on a formula that included those factors, breastfeeding status was categorized as low (less than 6 breast milk-months) and adequate (at least 6 breast milk-months).

The subscapular-to-triceps skinfold ratio (STR) was calculated to assess regional differences in subcutaneous fat distribution. In addition, an MRI of the

abdominal region was used to quantify VAT and SAT.

The mean age was 9.6 years for exposed youth and 10.6 years for unexposed youth at the study visit – a difference that was significant. Exposed youth were significantly more likely to be non-Hispanic white or Hispanic, and a larger proportion of exposed youth self-reported a Tanner stage less than 2 (prepubertal). Mothers with diabetes

during pregnancy were significantly older on average than mothers whose pregnancies were not complicated by diabetes. Exposed and unexposed offspring were not significantly different in terms of intrauterine growth, socioeconomic factors, or infant feeding practices.

Among adolescents with low breastfeeding status, exposure to diabetes in utero was associated with a 1.7-kg/m² greater BMI, a 5.8-cm greater waist cir-

Easy to teach¹

– Can be used in 6 straightforward steps

Easy to use¹

– Only long-acting insulin pen in which dose can be set from 1 to 80 units in 1-unit steps, dialed both up and down
– Once opened, Lantus[®] SoloSTAR[®] can be used for up to 28 days and is not refrigerated

Easy to inject¹

– Dose cannot be dialed past the number of units left in the pen
– It is important to keep the injection button pressed all the way in and to **slowly count to 10 before withdrawing the needle from the skin**. After a full injection, the number in the dose window will return to zero. These steps help ensure that the full dose has been delivered

Indications and Usage for Lantus[®]

Lantus[®] is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus[®] should be administered once a day at the same time every day.

Important Limitations of Use: Lantus[®] is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Important Safety Information for Lantus[®]

Contraindications

Lantus[®] is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and Precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus[®] with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus[®] via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus[®], and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus[®] dose may be required in patients with renal or hepatic impairment.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Other adverse reactions commonly associated with Lantus[®] are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus[®] SoloSTAR[®]

Lantus[®] SoloSTAR[®] is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Please see brief summary of full prescribing information for Lantus[®] on the following pages.

References: 1. Data on file, sanofi-aventis U.S. LLC. 2. Lantus Prescribing Information. April 2010.

cumference, a 6.1-cm² higher VAT, a 44.6-cm² greater SAT, and a 0.11-point higher STR, all significant differences. The association between exposure to diabetes in utero and the adiposity parameters was substantially reduced and not significant for adolescents with adequate breastfeeding in infancy with a 0.7-kg/m² lower BMI; a 2.7-cm greater waist circumference; a 2.1-cm² greater VAT; a 23.4-cm² greater SAT; and a 0.05-point greater STR among exposed versus unexposed children.

The authors reported that they have no relevant financial disclosures. ■

VIEW ON THE NEWS

Study Supports Breastfeeding

Dr. Andreas Plagemann and Dr. Thomas Harder noted that these findings may help answer key questions for the rapidly expanding fields of perinatal programming and developmental origins of health and disease.

“Differentiation and maturation, however, of affected organs and systems, such as the pancreas, adipose tissue, and brain, are not finished at birth. The question therefore arises

whether a prolongation of these critical exposures into the neonatal period might have similar effects,” they wrote.

The question of whether continuing exposure after birth to altered fuels through breastfeeding might have consequences for child development. “This study by Crume et al. further supports the notion that a long-term breastfeeding (i.e., longer than 6 months) has a protective effect on

later overweight risk in [offspring of diabetic mothers],” they wrote.

DR. PLAGEMANN is head of the division of experimental obstetrics at Charité-University Medicine Berlin. DR. HARDER also is a member of that organization. They reported that they had no relevant financial relationships. They commented in an editorial that accompanied the article by Crume et al. (*Diabetes Care* 2011;34:779-81).

For patients with diabetes using an insulin vial and syringe

Take aim with the Lantus® SoloSTAR® pen^a

50% more insulin per prescription^b of Lantus® SoloSTAR® for the same co-pay as a vial and syringe on most insurance plans

Prefilled with Lantus®, the only 24-hour insulin approved exclusively for use once a day to help patients with diabetes aim toward glycemic control²

Scan the QR code with your mobile phone for more information about Lantus® and Lantus® SoloSTAR®.

Here's how to get started:

1. Visit 2dscan.com or search for “ScanLife” in your app store or text “SCAN” to 43588
2. Follow the prompts to download the free application
3. Using the application, take a photo of the QR code through the ScanLife application



Once-Daily
24-HOUR

LANTUS® SoloSTAR®
insulin glargine [rDNA origin] injection

STARring the #1-prescribed insulin^c

^aThe SoloSTAR® pen is recommended for use with Becton, Dickinson and Company pen needles.

^bDepending on how prescription is written.

^cBased on TRx data from IMS Health, NPA™ Monthly database, time period from May 2003 to June 2010.

sanofi aventis

Because health matters.

US.GLA.11.02.020

© 2011 sanofi-aventis U.S. LLC